Neovacs Valuation Multiples

Neovacs Overview

About Neovacs

Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.

Founded

1993

HQ

Employees

24

Website

neovacs.fr

Sectors

BiopharmaceuticalsBioTech

Financials (FY)

Revenue: $423K

EBITDA: ($30M)

Market Cap

$1K

Valuation Multiples

Multiples.vc

Start free trial

Neovacs Financials

Neovacs reported last fiscal year revenue of $423K and negative EBITDA of ($30M).

In the same fiscal year, Neovacs generated $49K in gross profit, ($30M) in EBITDA losses, and had net loss of ($38M).

Neovacs P&L

In the most recent fiscal year, Neovacs reported revenue of $423K and EBITDA of ($30M).

Neovacs expects next 12-month revenue of XXX and NTM EBITDA of XXX

Neovacs Stock Performance

Neovacs has current market cap of $1K.

Neovacs' stock price is $0.00.

Neovacs Valuation Multiples

Neovacs trades at (0.6x) EV/Revenue multiple, and 0.0x EV/EBITDA.

Neovacs Financial Valuation Multiples

As of March 30, 2026, Neovacs has market cap of $1K.

Equity research analysts estimate Neovacs' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Neovacs has a P/E ratio of 0.0x.

Neovacs Margins & Growth Rates

Neovacs' revenue in the last fiscal year declined by (31%).

Neovacs' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.

Neovacs Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Neovacs M&A Activity

Neovacs acquired XXX companies to date.

Last acquisition by Neovacs was on XXXXXXXX, XXXXX. Neovacs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Neovacs Investment Activity

Neovacs invested in XXX companies to date.

Neovacs made its latest investment on XXXXXXXX, XXXXX. Neovacs invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).